Business
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
BEVERLY HILLS, CA / ACCESSWIRE / October 15, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"BEVERLY HILLS, CA / ACCESSWIRE / October 15, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce its abstract \"GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts\" has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition as detailed below:Session Name: 704. Immunotherapies: Beyond T to NKSession Date: Saturday, December 5, 2020Session Time: 7:30 AM - 9:00 AMPresentation Time: 8:00 AMThe ASH Annual Meeting & Exposition is the premier event in malignant and non-malignant hematology. ASH has more than 18,000 members from nearly 100 countries. ASH is the world's largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.In addition to the presentation, your abstract will also be published online in November supplemental issue of the journal Blood. First publication will be in the online ASH meeting program on November 5, 2020.Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented \"we are pleased to have the opportunity to present our interim results for GTB-3550 TriKE™ for the treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) patients.\"About GT Biopharma, Inc.GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and infectious disease therapeutic products based our proprietary Tri-specific Killer Engager (TriKE™) platform. Our TriKE™ platform is designed to harness and enhance the cancer cell and virus infected cell killing using the patient's immune system NK cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using proprietary TriKE™ technology developed by researchers at the university to target NK cells.About GTB-3550 TriKE™ FDA Clinical TrialGTB-3550 is the Company's first TriKE™ product candidate b...